<DOC>
	<DOC>NCT00647244</DOC>
	<brief_summary>To evaluate the efficacy and safety of switching from Retrovir to Tenofovir or Abacavir in HIV-infected patients</brief_summary>
	<brief_title>Efficacy and Safety of Switching From Retrovir to Tenofovir or Abacavir in HIV-infected Patients</brief_title>
	<detailed_description />
	<mesh_term>HIV Infections</mesh_term>
	<mesh_term>Tenofovir</mesh_term>
	<mesh_term>Abacavir</mesh_term>
	<mesh_term>Dideoxynucleosides</mesh_term>
	<criteria>HIVinfection with undetectable viral load Antiretroviral treatment including Retrovir for more than three months If fertile female: Negative pregnancy test and use of safe contraception Negative HBsantigen titer Prior treatment with abacavir or tenofovir Resistance towards abacavir or tenofovir Tissue type HLAB5701 Renal disease Diabetes Mellitus Osteoporosis Pregnant or lactating subjects Intravenous drug abuse Hypersensitivity towards drugs or active ingredient used ALAT &gt; 5 times upper normal level Current alcohol or substance abuse judged by the Investigator to potentially interfere with subject compliance</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>December 2010</verification_date>
	<keyword>Tenofovir</keyword>
	<keyword>Abacavir</keyword>
	<keyword>Antiretroviral therapy</keyword>
	<keyword>HIV</keyword>
	<keyword>Nucleoside analogue reverse transcriptase inhibitor</keyword>
</DOC>